Abstract
Escherichia coli (E. coli) K1 sepsis and meningitis is a severe infection characterized by high mortality in neonates. Successful colonization and translocation across the intestinal mucosa have been regarded as the critical steps for E. coli K1 sepsis and meningitis. We recently reported that the probiotic mixture, Golden Bifido (containing live Lactobacillus bulgaricus, Bifidobacterium, and Streptococcus thermophilus, LBS) has a preventive role against neonatal E. coli K1 bacteremia and meningitis. However, the interaction between the neonatal gut barrier, probiotics and E. coli K1 is still not elucidated. The present study aims to investigate how LBS exerts its protective effects on neonatal gut barrier during E. coli K1 infection. The beneficial effects of LBS were explored in vitro and in vivo using human colon carcinoma cell lines HT-29 and rat model of neonatal E. coli K1 infection, respectively. Our results showed that stimulation with E. coli K1 was able to cause intestinal barrier dysfunction, which were reflected by E. coli K1-induced intestinal damage and apoptosis of intestinal epithelial cells, reduction of mucin, immunoglobulin A (IgA) and tight junction proteins expression, as well as increase in intestinal permeability, all these changes facilitate E. coli K1 intestinal translocation. However, these changes were alleviated when HT-29 cells were treated with LBS before E. coli K1 infection. Furthermore, we found that LBS-treated neonatal rats (without E. coli K1 infection) have showed higher production of mucin, ZO-1, IgA, Ki67 in intestinal mucosa as well as lower intestinal permeability than that of non-treated rats, indicating that LBS could accelerate the development of neonatal intestinal defense. Taken together, our results suggest that enhancement of the neonatal intestinal defense to fight against E. coli K1 translocation could be the potential mechanism to elucidate how LBS confers a protective effect against neonatal E. coli K1 bacteremia and meningitis. This indirect mechanism makes LBS exert preventive effect on most of gut-derived pathogenic infections rather than only E. coli.
Highlights
Bacterial sepsis and meningitis are regarded as severe infections that lead to high morbidity and mortality during the neonatal period (Bhagat et al, 2015)
As the mucin layer is the first barrier that E. coli K1 encounter in the intestine (Corfield et al, 2001; Kim and Ho, 2010), we initially explored the possibility of LBS protecting the mucin from E. coli K1-induced degradation
E. coli principally resides in the gut, but could translocate to distant organs such as the bladder and brain, where they can cause urinary tract infections and meningitis
Summary
Bacterial sepsis and meningitis are regarded as severe infections that lead to high morbidity and mortality during the neonatal period (Bhagat et al, 2015). Among the bacterial pathogens causing sepsis and meningitis, the most common is Escherichia coli (E. coli) K1 (Glode et al, 1977). The excessive, even indiscriminate use of antibiotics may increase the incidence of neonatal infections with antibiotic-resistant E. coli as well as reduces the efficacy of conventional antibiotic chemotherapy. The incidence of early onset E. coli infections and ampicillin-resistant E. coli infections has been increased rapidly in low birth weight infants (Simonsen et al, 2014). Given the seriousness of neonatal E. coli K1 infection, development of a non-antibiotic strategy for prevention and treatment has emerged as an urgent issue
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.